Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial
pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in …

Idiopathic pulmonary fibrosis (IPF) is a dramatic disease without cure. The US Food and
Drug Administration–approved drugs, pirfenidone and nintedanib, only slow disease …

Idiopathic pulmonary fibrosis (IPF) is a life-threatening progressive lung disorder with limited
therapeutic options. While interleukin-10 (IL-10) is a potent anti-inflammatory and anti …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease
associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient …

Background Observational studies suggest an association between reduced lung function
and risk of coronary artery disease and ischaemic stroke, independent of shared …

Pulmonary fibrosis (PF) is a fibrotic interstitial pneumonia with poor prognosis and limited
treatment methods. Inhibition of integrin α V β 6 expression could prevent pulmonary …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia
that mainly affects the elderly. Several reports have demonstrated that aging is involved in …

Background Nintedanib represents an antifibrotic compound able to slow down disease
progression of patients with idiopathic pulmonary fibrosis (IPF). Objective To investigate the …

Abstract Sphingosine-1-phosphate (S1P), a simple, bioactive sphingolipid metabolite, plays
a key role, both intracellularly and extracellularly, in various cellular processes such as …

Idiopathic pulmonary fibrosis (IPF) is a lung-limited and progressive fibrotic disease. The
early diagnosis and therapies of IPF are still full of clinical challenges. Glutathione S …